⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

OGN · Organon & Co.

$13.54 latest stored close
Detected setup Flat Base

Watch · Quality 22/100

Ask about OGN

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Health Technology / OGN

$OGN

Organon & Co.

Organon & Co. is a mid-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $4B.

Strong Buy · 93 Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 1 Data 1h 2m ago
$13.54 latest close
Council read · 6 methods

Watch — evidence is building

0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.

Earnings-risk mode

Pre-earnings setup

Tuesday, August 4, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

OGN+0.15%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
Same completed session window ending 2026-07-27. OGN was -0.36 points vs XLV. +0.13 points vs SPY.
CatalystUnavailable Stock reactionPositive Sector reactionSupportive Opening surgeUnavailable Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $13.54 Jul 27 close
52W High $13.60 -0.4%
52W Low $5.69
Wks Since High 3w
Base Depth -1.0%
Tight Wks 12
Base B1
SMA 50 $13.45
SMA 200 $9.47
Avg Vol 2,734,026
RS Rank 79
RS vs High -2.3%
RS Slope +0.2% ▲
Grp Rank #16/64
ADR% 0.3%
ATR(14) $0.04 (0.3%)
Rel Vol (today) 0.97×
Vol Pace N/A
U/D Vol 1.50
A/D Days 21A / 13D
A/D Rating A+
VDU Bars 0/10 d
Power Trend 30d
Earnings 7d
$5.69
$13.60 99%

OGN Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for OGN.

Create Free Account
Setup Quality B+ 5/7 signals
Jul 24: 93 (Pocket Pivot)Jul 27: 93 (Flat Base)Jul 28: 93 (Flat Base)93 Score trend
✓ Stage 2 · Advancing ✓ Power Trend 30d ✗ RS New High ✓ Trend 8/8 ✗ No Pattern ✓ CANSLIM 72.2 (B) ✓ Gatekeeper Base #1 (A)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$OGN · $13.54 · as of 2026-07-27 · multi-factor read
93
/ 100
Strong Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$13.45 ↑
100-day$11.10 ↑
200-day$9.47 ↑
Bullish (50 > 200)

RSI (14)

Reading62.4 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateWeakening
Histogram-0.020

Weakening — MACD slipped below its signal line. Histogram expanding.

Bollinger Bands (20,2)

%B / Width71% · 0.8%
Squeeze — volatility compressing

Mid-band — no directional band edge in play. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol1.5 · Accumulation
Rel volume0.97×

Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.

Support & Resistance

R · $13.6052-week high
Price · $13.54now
S · $13.45swing level
S · $8.51swing level
S · $6.50swing level

Fibonacci · Uptrend swing

23.6%$11.73
38.2%$10.58
50.0%$9.64
61.8%$8.71
78.6%$7.38

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for OGN — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume accumulation
Want this read in a legend's voice? 💬 Ask a Legend about OGN
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B

Trend-template read: 10/12 pass; wait for the soft misses to improve.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $13.54, MA150 $10.05, MA200 $9.47
1.2 150-day MA > 200-day MAMA150 $10.05 vs MA200 $9.47
Failing evidence
2. Quarterly EPS growth ≥ 25%+12.7% QoQ
2. Revenue growth ≥ 20% YoY-2.9% YoY
10/12 checks
Avoid
O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
A: Annual earnings & revenue qualityRev -2.9% | ROE 29.9%
N: Near 52-week high or RS line new high0.4% below high | RS line new high: False
Failing evidence
C: Quarterly EPS acceleration ≥ 25%+12.7% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 76
3/8 checks
Watch
Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $13.54 vs MA200 $9.47
Failing evidence
Volume expansion above averageVolume ratio 0.97x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
5/7 checks
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$13.54
Relative strengthRS 76
Failing evidence
Volume vs average0.97x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Watch
Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$13.54
Relative strengthRS 76
Failing evidence
Volume vs average0.97x
Box top broken on heavy volumeNot confirmed
4/6 checks
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$13.54
Relative strengthRS 76
Failing evidence
Volume vs average0.97x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
4/6 checks
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
117RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +6 A+
A: 11 D: 5 Net: +665 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B 4/7 SEPA
Separate score from the 8-point Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ +13%
Revenue growth ≥20% YoY -3%
Gross margin ≥30% 53%
ROE ≥17% 30%
RS rating ≥80 (leadership) 76
Stage 2 uptrend (Weinstein) Stage 2
Within 25% of 52W high -0.4%

Method Playbook

📋 Trade it like Minervini EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
Minervini B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the tight base's structural pivot; the setup must retain Trend Template leadership into the trigger.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a decisive move through the pivot with volume confirmation, and do not initiate more than 5% above it.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start at the tighter structural invalidation; the initial loss limit must not exceed roughly 7–8% from entry.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Hold the initial stop until the trade proves itself; near +1R move to breakeven, then trail a higher low or rising 10/21-day average once well extended.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit when the structural stop or a meaningful higher-low/short-term trend violation fires; never widen the stop.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

92.6 score
RS Score 76
Trend 8/8
CANSLIM 72.2* (B)
depth pct: 1.8 base days: 35 prior uptrend pct: 139.0 weekly close spread pct: 1.2 vol dried: ✓ validation reason: valid generic setup multi tf evaluated: ✓ multi tf reason: weekly trend template 8/8 confirmed
Why This Setup?
Flat Base

Flat Base: 35d base, depth 1.8%, prior uptrend 139%. Pivot $13.60. | Strong trend (8/8) | Good RS (76) | High-confidence pattern (100%) | Accumulation (1.5× up/dn vol) | Power Trend | Stage 2 | Tight base (12 tight wks) | Readiness 65/100 (watch) | CANSLIM 72.2 (B)

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

1/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

8/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $13.54 vs SMA150 $10.05 / SMA200 $9.47
SMA 150 above SMA 200 SMA150 $10.05 vs SMA200 $9.47
SMA 200 trending up Slope +0.30 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $13.45
Price above SMA 50 $13.54 vs SMA50 $13.45
30%+ above 52W low +138.0% from $5.69
Within 25% of 52W high -0.4% from $13.60
RS score above 70 RS 76

Fundamentals

52W Range
99%
Mkt Cap SEC
3.6B
EPS QoQ
+13%
Rev YoY
-3%
ROE
30%
Gross Margin
53%
D/E
11.49
EPS TTM
$0.72
P/E TTM
18.8x
Float
263M
Insider
No Buy

Company

Legend AI snapshot
Organon & Co.
OGN · NYSE · Health Technology · Pharmaceuticals: Major
$13.54latest close $3.6Bmarket cap 79RS rank 93setup score
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
B 72.2* CANSLIM * disqualified on C, M
C · Curr. EPS
74
A · Annual EPS
74
N · New Highs
100
S · Supply/Demand
55
L · Leader RS
76
I · Inst. Spons.
100
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
8/8
W. RS
99
W. Support
$5.69
W. Resist
$13.60
Weekly Structure

Scan History

20× streak
Jul 24: 93 (Pocket Pivot)Jul 27: 93 (Flat Base)Jul 28: 93 (Flat Base)93
Jul 28
Flat Base ✓ Gate
93
Jul 27
Flat Base ✓ Gate
93 0.0%
Jul 24
Pocket Pivot ✓ Gate
93 +0.1%

Get the full picture on OGN

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial